Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

被引：2

作者：

Mansilla-Polo, Miguel ^{[1
,2
]}

Pons-Benavent, Marti ^{[3
]}

Fernandez-Crehuet, Pablo ^{[4
]}

Vilarrasa, Eva ^{[5
]}

Albanell-Fernandez, Cristina ^{[6
]}

Morales-Tedone, Enrico ^{[6
]}

Rausell-Felix, Francisca ^{[6
]}

Alcala-Garcia, Rebeca ^{[7
]}

Matellanes-Palacios, Maria ^{[7
]}

Martin-Ezquerra, Gemma ^{[8
]}

Alfageme, Fernando ^{[9
]}

Ciudad-Blanco, Cristina ^{[10
]}

Lopez-Villaescusa, Maria Teresa ^{[11
]}

Garbayo-Salmons, Patricia ^{[12
]}

Martorell, Antonio ^{[13
]}

Escutia-Munoz, Begona ^{[1
,2
]}

Navarro-Blanco, Fernando ^{[1
,2
]}

Martin-Torregrosa, Daniel ^{[1
,2
]}

Cuenca-Barrales, Carlos ^{[14
]}

Molina-Leyva, Alejandro ^{[14
]}

Botella-Estrada, Rafael ^{[1
,2
,15
]}

机构：

[1] Hosp Univ & Politecn La Fe, Dept Dermatol, 106 Ave Fernando Abril Martorell, Valencia 46026, Spain

[2] Inst Invest Sanitaria IIS La Fe, Valencia, Spain

[3] Hosp Virgen Lirios, Dept Dermatol, Alicante, Spain

[4] Hosp Reina Sofia, Dept Dermatol, Cordoba, Spain

[5] Hosp Santa Creu St Pau, Dept Dermatol, Barcelona, Spain

[6] Hosp Clin Univ, Dept Dermatol, Valencia, Spain

[7] Hosp Sagunto, Dept Dermatol, Valencia, Spain

[8] Hosp Mar, Dept Dermatol, Barcelona, Spain

[9] Hosp Univ Puerta Hierro, Dept Dermatol, Madrid, Spain

[10] Hosp Univ Gregorio Maranon, Dept Dermatol, Madrid, Spain

[11] Complejo Hosp Univ Albacete, Dept Dermatol, Albacete, Spain

[12] Hosp Parc Tauli Sabadell, Dept Dermatol, Barcelona, Spain

[13] Hosp Manises, Dept Dermatol, Valencia, Spain

[14] Hosp Univ Virgen Nieves, Dept Dermatol, Granada, Spain

[15] Univ Valencia, Fac Med, Valencia, Spain

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2024年 / 65卷 / 07期

关键词：

bimekizumab; biologic therapy; effectiveness; hidradenitis suppurativa; safety;

D O I：

10.1111/ajd.14339

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.

引用

页码：e198 / e202

页数：5

共 50 条

[1] Real-world effectiveness and safety of the LAight-therapy in patients with hidradenitis suppurativa
Strobel, Alexandra
Schultheis, Michael
Staubach, Petra
Grabbe, Stephan
Mann, Caroline
Hennig, Katharina
Szepietowski, Jacek C.
Matusiak, Lukasz
Krajewski, Piotr
von Stebut, Esther
Garcovich, Simone
Bayer, Hans
Heise, Marcus
Podda, Maurizio
Kirschner, Uwe
Nikolakis, Georgios
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, : 936 - 945
[2] Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan
Hayashi, Nobukazu
Hayama, Koremasa
Takahashi, Kenzo
Kurokawa, Ichiro
Okazaki, Masateru
Kashiwagi, Tomoko
Iwashita, Eri
Terui, Tadashi
JOURNAL OF DERMATOLOGY, 2023, 50 (08) : 1034 - 1044
[3] Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study
Cai, Jianpeng
Wang, Hongyu
Ye, Xiaoting
Lu, Shengjia
Tan, Zhili
Li, Zhonghua
Lin, Dan
Qian, Jiancheng
Lu, Xiaoxian
Wan, Jiaolong
Wang, Jie
Ai, Jingwen
Pu, Yonglan
Qu, Lihong
Wang, Sen
FRONTIERS IN MICROBIOLOGY, 2024, 15
[4] Management and Burden of Hidradenitis Suppurativa: An Italian Hybrid Real-World Study
Anna Balato
Marina Venturini
Massimiliano Scalvenzi
Caterina Foti
Giovanni Maifredi
Simona Serao Creazzola
Stefania Antonacci
Arianna Tonelli
Diletta Valsecchi
Donatella Vassellatti
Riccardo Cipelli
Alessandra Ori
Lucia Casoli
Dermatology and Therapy, 2025, 15 (7) : 1771 - 1785
[5] Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study
Kozera, Emily
Flora, Akshay
Frew, John W.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) : 1440 - 1442
[6] Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study
Hagino, Teppei
Saeki, Hidehisa
Fujimoto, Eita
Kanda, Naoko
JOURNAL OF DERMATOLOGY, 2024, 51 (05) : 649 - 658
[7] Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies
van Pesch, Vincent
Sindic, Christian J.
Fernandez, Oscar
CLINICAL NEUROLOGY AND NEUROSURGERY, 2016, 149 : 55 - 63
[8] Efficacy and safety of a combined pharmacological and surgical approach in patients affected by hidradenitis suppurativa: data from a retrospective real-world clinical study
Malvaso, Dalma
Chiricozzi, Andrea
Fossati, Barbara
Antonelli, Flaminia
Peris, Ketty
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2024, 159 (02) : 190 - 195
[9] Secukinumab Treatment in Patients with Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
Erbagci, Ece
Bakay, Ozge Sevil Karstarli
Hapa, Fatma Asli
DERMATOLOGY PRACTICAL & CONCEPTUAL, 2025, 15 (01):
[10] Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study
Vanasse, A.
Blais, L.
Courteau, J.
Cohen, A. A.
Roberge, P.
Larouche, A.
Grignon, S.
Fleury, M-J.
Lesage, A.
Demers, M-F.
Roy, M-A.
Carrier, J-D.
Delorme, A.
ACTA PSYCHIATRICA SCANDINAVICA, 2016, 134 (05) : 374 - 384

← 1 2 3 4 5 →